Exdensur (depemokimab) China approval has been officially confirmed by GSK, marking a historic shift in the treatment landscape for respiratory diseases in the region. The National Medical Products Administration (NMPA) has granted marketing authorization for Exdensur (depemokimab) as an add-on maintenance treatment for adults with severe eosinophilic asthma (SEA).
This decision makes Exdensur the first ultra-long-acting biologic approved in China that targets interleukin-5 (IL-5) with a distinct twice-yearly dosing schedule. For millions of patients struggling with the burden of daily or monthly treatments, this approval represents a significant step toward improved adherence and long-term stability.
The Impact of Exdensur Depemokimab China Approval on Respiratory Care
The Exdensur depemokimab China approval addresses a critical unmet need in a country where asthma prevalence is rising. Traditional biologics for severe asthma typically require injections every four to eight weeks. However, Exdensur’s high binding affinity for IL-5 allows it to remain effective in the body for much longer periods.
By reducing the frequency of administration to just two doses per year, healthcare providers believe this will significantly reduce the “treatment burden” on patients. This long-acting profile ensures that patients have continuous protection against severe asthma attacks (exacerbations) without the frequent clinic visits required by older generation biologics.
Read More: Exdensur (depemokimab) China approval: A Paradigm Shift in Severe Asthma Treatment
Clinical Significance Behind the Exdensur Depemokimab China Approval
The NMPA’s decision was heavily supported by the positive results from the SWIFT-1 and SWIFT-2 Phase III clinical trials. These global studies demonstrated that depemokimab achieved a statistically significant reduction in the annualized rate of moderate-to-severe exacerbations compared to the placebo over 52 weeks.
Key data highlights from the trials include:
- A 54% reduction in clinincally significant exacerbations.
- Improved lung function and quality of life scores for patients.
- A safety profile consistent with existing IL-5 therapies.
Read More: FDA Approves GSK’s Exdensur (depemokimab), the First Twice-Yearly Biologic for Severe Asthma
How Exdensur Depemokimab China Approval Changes Patient Outcomes
For patients in China, the Exdensur depemokimab China approval means more than just fewer needles. Severe eosinophilic asthma is characterized by an overproduction of eosinophils, a type of white blood cell that causes airway inflammation. By consistently suppressing these cells for six months with a single dose, Exdensur helps prevent the irreversible lung damage often associated with chronic asthma flares.
Future Outlook for GSK in China
Following the Exdensur depemokimab China approval, GSK is expected to work closely with local health authorities to ensure the drug is included in the National Reimbursement Drug List (NRDL). This would make the therapy accessible and affordable for a larger portion of the population.
As GSK continues to expand its portfolio, this approval sets a high bar for competitors in the biologic space. The introduction of twice-yearly dosing is likely to become the new gold standard for patient-centric care in severe asthma management.
